Description: Kangstem Biotech Co., Ltd., a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn's disease. It also provides stem cell conditioned media, such as umbilical cord blood-derived stem cell conditioned media that includes epidermal, vascular endothelium, keratinocyte, hepatocyte, transforming, and platelet-derived growth factors, as well as growth and differentiation factor 11, and Fibroblast growth factor 2 for skin growth and regeneration. In addition, the company offers stem cell culture media, including KSB-3 kit, a medium for culturing the human mesenchymal stem cell; and cell freezing and thawing platform. Further, it provides pharmaceutical contract manufacturing and development services. Kangstem Biotech Co., Ltd. was founded in 2010 and is headquartered in Seoul, South Korea.
Home Page: www.kangstem.com
Sinan Building
Seoul,
South Korea
Phone:
82 2 888 1590
Officers
| Name | Title |
|---|---|
| Mr. Tae-Wha Lee | Sr. VP and Internal Director |
| Dr. Kwang-Won Seo | VP and Internal Director |
Exchange: KQ
Country: KR : Korea (Republic of)
Currency: Korean Won (₩)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 8.1981 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 91 |